Search clinical trials for: Peginterferon alfa2a

Total 2828 results

Hoffmann-La Roche

Completed

A Study of Pegasys (Peginterferon Alfa-2a) Added to Nucleos(t)Ide Analogue Treatment in Participants With HBeAg-Negative Chronic Hepatitis B Genotype D Showing Stable Hepatitis B Virus (HBV) Deoxyribonucleic Acid (DNA) Suppression

Hepatitis B, Chronic

Italy
National Taiwan University Hospital
Roche Pharma AG

Unknown

Pegasys Plus Entecavir Versus Entecavir Versus Pegasys for Hepatitis B e Antigen-Negative Chronic Hepatitis B

Chronic Hepatitis B

Taiwan
Grupo de Enfermedades Infecciosas de la Sociedad...

Unknown

Epidemiological Study to Evaluate Personality Disorders in Prison Populations in Treatment for Hepatitis C (Perseo)

Hepatitis C, Chronic | Personality Disorders in Prison

Spain
University Hospital, Geneva

Completed

Ribavirin/Pegasys Treatment of Recurrent Hepatitis C After Liver Transplant

Hepatitis C
Merck Sharp & Dohme LLC

Completed

A Pharmacokinetics/Pharmacodynamics Study of SCH 900518 in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C (Protocol No. P05104AM2)(COMPLETED) (NEXT-1)

Hepatitis C, Chronic
Hoffmann-La Roche

Completed

An Observational Study of Peginterferon Alfa-2a Plus Ribavirin for Hepatitis C Virus (HCV) Infection in Austria

Hepatitis C

Austria
Merck Sharp & Dohme LLC

Completed

Pharmacokinetics of Peginterferon Alfa-2b in Participants With Moderate and Severe Renal Impairment (P05655)

Renal Insufficiency
Theodor Bilharz Research Institute

Unknown

Boceprevir With Peginterferon Alfa-2b and Ribavirin in the Treatment-naive Patients Infected With Genotype 4 Chronic Hepatitis C Infection

Genotype 4 Chronic Hepatitis C Infection

Egypt
National Institute of Allergy and Infectious Diseases...

Completed

Pegylated Interferon Alfa-2a Maintenance Therapy and Liver Disease Progression in People Infected With Both HIV and Hepatitis C Virus (HCV)

HIV Infections | Hepatitis C | Liver Disease

United States, Puerto Rico
Hospital Carlos III, Madrid

Unknown

Phase IV Study to Evaluate the Efficacy/Safety to Extend Treatment and High Dose of Ribavirin in co-Infected Patients (PERICO)

Chronic Hepatitis C

Spain
Nanogen Pharmaceutical Biotechnology Joint Stock...

Completed

The Study of Safety, Pharmacokinetics, Pharmacodynamics of Peglamda (Peginterferon Lamda 1) on Healthy Volunteers and the Preliminary Evaluation of Peglamda and Hepasig (Ribavirin) Treatment's Effects on Chronic Hepatitis C Patients

Hepatitis C

Vietnam
Hoffmann-La Roche

Withdrawn

A Study of RO5024048 in Combination With Ritonavir-Boosted Danoprevir and Pegasys/Copegus in Patients With Chronic Hepatitis C Genotype 1 Who Have Failed Prior HCV Protease Inhibitor Treatment

Hepatitis C, Chronic
Amr Hafez
Ain Shams University

Completed

Comparison of Pegasys Versus Peg-Intron for Treatment of Chronic Hepatitis C Genotype 4

Hepatitis C
University of Hamburg-Eppendorf
Hoffmann-La Roche; Universitätsklinikum Hamburg-Eppendorf

Unknown

Study for Patients With Chronic HCV (GT 1 or 3) Who Relapsed to Previous (Peg)Interferon/ Ribavirin Combination Therapy

Hepatitis C, Chronic | Relapse

Germany
Weill Medical College of Cornell University
Merck Sharp & Dohme LLC

Terminated

Pegylated Interferon Alpha-2b in Early Primary Myelofibrosis

Myelofibrosis

United States
Hoffmann-La Roche

Completed

A Study of Ritonavir-Boosted Danoprevir (RO5190591) in Combination With Pegasys and Ribavirin in Patients With Chronic Hepatitis C Genotype 1

Hepatitis C, Chronic

New Zealand, Poland, France
Hoffmann-La Roche

Completed

A Study of Ritonavir-Boosted Danoprevir and RO5024048 in Different Combinations in Null Responder or Treatment-Naïve Patients With Chronic Hepatitis C and Compensated Cirrhosis

Hepatitis C, Chronic

United States, Canada, Slovakia, Poland, New Zealand, France, Australia
Aiwu Ruth He, MD
Merck Sharp & Dohme LLC; Georgetown University; The Cleveland Clinic; Hoosier Cancer... and other collaborators

Terminated

Evaluating Combination Immunotherapy for Advanced Cholangiocarcinoma With Pembrolizumab and PEG-Intron

Advanced Cholangiocarcinoma

United States
Weill Medical College of Cornell University
Vertex Pharmaceuticals Incorporated

Completed

Intrahepatic HCV RNA and Telaprevir Kinetics in Hepatitis C Virus (HCV)

Hepatitis C
Hoffmann-La Roche

Completed

A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) Plus COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C (CHC) Genotype 1 and Human Immunodeficiency Virus-1 (HIV-1) Co-infection

Hepatitis C, Chronic
Merck Sharp & Dohme LLC

Completed

Post-marketing Surveillance of HIV-infected Patients With Chronic Hepatitis C Treated With PegIntron Pen and Rebetol (Study P04584)

HIV Infections | Hepatitis C | Chronic Hepatitis C
Merck Sharp & Dohme LLC

Terminated

Efficacy and Safety of Short Course Therapy With Peginterferon Alpha-2b (PEG-IFN Alfa-2b) and Ribavirin (RBV) for Chronic Hepatitis C (Genotype 4) Participants Achieving a Rapid Virological Response at Week 4 of Treatment (MK-8908B-059) (START 4)

Hepatitis C, Chronic
Hoffmann-La Roche

Completed

An Observational Study of Peginterferon Alfa-2a in Combination With Ribavirin in Participants With Chronic Hepatitis C and Compensated Liver Cirrhosis (STANDART)

Hepatitis C, Chronic

Russian Federation, Korea, Republic of
University of Chicago

Terminated

Pegylated Interferon, Ribavirin, Telaprevir in Hepatitis C Virus Infection in Orthotopic Liver Transplant Recipients

Hepatitis C

United States
Kirby Institute

Completed

Treatment of Recently Acquired Hepatitis C Virus Infection (ATAHC-II)

Acute Hepatitis C

Australia
Chugai Pharmaceutical

Completed

Trial of Pegasys® in Patients With Chronic Hepatitis C

Chronic Hepatitis C

Japan
Hoffmann-La Roche

Completed

A Study of Hepatitis C Virus (HCV) Polymerase Inhibitor Pro-Drug in Combination With PEGASYS Plus COPEGUS Compared With PEGASYS Plus COPEGUS in Patients With Chronic Hepatitis C Genotype 1 Infection.

Hepatitis C, Chronic

Australia, France, Italy, Spain, Germany, United States, Canada, Austria, Puerto Rico
Mitsubishi Tanabe Pharma Corporation

Completed

Efficacy and Safety of MP-424, Peginterferon Alfa-2b and Ribavirin in Relapser Genotype 2 Hepatitis C Infected Patients

Chronic Hepatitis C

Japan
National Taiwan University Hospital

Not yet recruiting

Clinical Study for the Efficacy and Safety of Ropeginterferon Alfa-2b in Adult COVID-19 Patients With Comorbidities

COVID-19

Taiwan
PharmaEssentia Japan K.K.

Recruiting

Extension Study of P1101 After Completion of Phase 2 Study in PV Patients or Phase 3 Study in ET Patients

Polycythemia Vera (PV)

Japan
Hoffmann-La Roche

Completed

A Study of Induction Dosing With Peginterferon Alfa-2a and Ribavirin in Participants With Chronic Hepatitis C (CHC) Genotype 1 Infection

Hepatitis C, Chronic

Australia, Canada, Mexico, New Zealand, Thailand, Argentina
Tibotec BVBA
Tibotec Pharmaceutical Limited

Completed

A Safety and Effectiveness Study of Telaprevir in Chronic, Genotype 1, Hepatitis C Patients That Failed Previous Standard Treatment

Hepatitis C, Chronic

United States, Australia, France, United Kingdom, Germany, Spain, Belgium, Israel, Canada, Brazil, Austria, Poland, Netherlands, Sweden, Switzerland, Puerto Rico
Hoffmann-La Roche

Completed

An Observational Study to Assess the Effect of Cumulative Ribavirin Dose in Participants With Chronic Hepatitis C

Hepatitis C, Chronic

Hungary
Mitsubishi Tanabe Pharma Corporation

Completed

Efficacy and Safety of MP-424, Peginterferon Alfa-2b and Ribavirin in Non-responder Genotype 2 Hepatitis C Infected Patients

Chronic Hepatitis C

Japan
ANRS, Emerging Infectious Diseases
Merck Sharp & Dohme LLC; Rennes University Hospital

Completed

Interest of Ribavirin in the Maintenance Treatment of Liver Fibrosis Using Low Dose Pegylated Interferon alpha2b in Patients With Chronic Hepatitis C Non Responders to Previous Antiviral Therapy.

Hepatitis C, Chronic | Liver Fibrosis

France, Belgium
Ascletis Pharmaceuticals Co., Ltd.

Completed

Efficacy and Safety of Danoprevir/r + PR 12-week Triple Therapy in Treatment-Naive, Non-Cirrhotic, G1 CHC China II

Chronic Hepatitis C
Hoffmann-La Roche

Completed

A Study of RO5024048 in Combination With Ritonavir-Boosted Danoprevir With or Without Copegus (Ribavirin) in Interferon-Naïve Patients With Chronic Hepatitis C Genotype 1 (INFORM-SVR)

Hepatitis C, Chronic

France, Germany, United States, New Zealand
Merck Sharp & Dohme LLC

Completed

Peginterferon α-2b as a Maintenance Therapy in Participants With Multiple Myeloma Who Responded to Induction Therapy (P01972-AM7)

Multiple Myeloma
Hoffmann-La Roche

Completed

A Study of Pegasys (Peginterferon Alfa-2a) Administered Alone or in Combination With Copegus (Ribavirin) in Patients With Chronic Hepatitis C Who Have Participated in Previous Pegasys Trials

Hepatitis C, Chronic

Australia, United States, Italy, France, Puerto Rico, Taiwan, United Kingdom, Greece, Poland, Brazil, Spain
Weill Medical College of Cornell University
Schering-Plough

Completed

Comparison of PEG-Intron and Two Different Doses of Ribavirin for the Treatment of Chronic Hepatitis C In Treatment Naïve Subjects

Chronic Hepatitis C
Hepatitis Resource Network
Hoffmann-La Roche

Completed

PEG-Interferon a-2b + Ribavirin for Treatment of Patients With Chronic Hepatitis C Who Have Previously Failed to Achieve a Sustained Virologic Response Following Interferon Alfa or Interferon a-2b + Ribavirin Therapy

Chronic Hepatitis C Virus Infection

United States
Eastern Cooperative Oncology Group
National Cancer Institute (NCI)

Completed

PEG-Interferon Alfa-2b in Treating Patients With Stage IV Melanoma

Melanoma (Skin)

United States
National Taiwan University Hospital

Completed

Clinical Study for the Efficacy and Safety of Ropeginterferon Alfa-2b in Moderate COVID19.

COVID-19

Taiwan
Medtronic Corporate Technologies and New Ventures

Completed

Safety and Efficacy Study to Compare Continuous Infusion of Interferon With Standard of Care for Chronic Hepatitis C (COPE-HCV)

Hepatitis C

United States
Pusan National University Hospital

Unknown

HBsAg Decline After Pegylated-interferon-α in e Antigen Positive Chronic Hepatitis B With Nucleoside Maintenance

Chronic Hepatitis B

Korea, Republic of
National Institute of Allergy and Infectious Diseases...

Completed

Safety and Tolerability of Pegylated Interferon (PEG-IFN) Alfa-2a in HIV Infected People

HIV Infections

United States
Merck Sharp & Dohme LLC

Terminated

Relapse Rate in Hepatitis C Patients Treated With Peginterferon Alfa-2b Plus Ribavirin in Common Clinical Practice in France (P05484)(Completed) (RE-CHUT)

Hepatitis C | Hepatitis C, Chronic
Ascletis Pharmaceuticals Co., Ltd.

Completed

Efficacy and Safety of Danoprevir/r + PR 12week Triple Therapy in Treatment Naive Non-Cirrhotic G1 CHC China III

Chronic Hepatitis C
Merck Sharp & Dohme LLC

Completed

5 Year Long-term Follow up in Pediatric Participants Who Received PegIntron Plus Rebetol in P02538 Part I (P02538 Pt 2)

Hepatitis C, Chronic
Gilead Sciences

Completed

Efficacy and Safety Study of GS-9256 and GS-9190 Alone and in Combination With Ribavirin for 28 Days in Patients With Chronic Hepatitis C Virus Infection

HCV Infection

Germany, Belgium, United Kingdom, France

3

Subscribe